Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study

An announcement from Stoke Therapeutics ( (STOK) ) is now available.

Stoke Therapeutics has secured alignment with global regulatory agencies for its Phase 3 EMPEROR study of zorevunersen, a potential first disease-modifying treatment for Dravet syndrome, with plans to begin the study by mid-2025. The study will evaluate the drug’s efficacy in reducing seizure frequency and improving cognitive and behavioral functions in children and adolescents, with a significant commercial opportunity for treating over 38,000 patients in major markets.

More about Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company focused on restoring protein expression using RNA medicine. It utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) for treating genetic disorders, primarily targeting diseases like Dravet syndrome.

YTD Price Performance: 1.95%

Average Trading Volume: 567,030

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $608.6M

For detailed information about STOK stock, go to TipRanks’ Stock Analysis page.